Expert Interviews

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

There is far less patient education for oral agents, such as CDK4/6 inhibitors for breast cancer, as there is for chemotherapy. This is a major issue, explained Patricia Jakel, MN, RN, AOCN, advanced practice nurse at UCLA's solid tumor program and co-editor in chief of Oncology Nursing News.